Ferrostatin-1 alleviates cytotoxicity of cobalt nanoparticles by inhibiting ferroptosis

Weinan Zhang a,*, Chen Wang b,*, Wenfeng Zhu b, Fan Liu a, and Yake Liu a

aDepartment of Orthopaedics, Affiliated Hospital of Nantong University, Nantong, Jiangsu Province, China; bDepartment of Orthopaedics, The Sixth Affiliated Hospital of Nantong University, Yancheng, Jiangsu Province, China

ABSTRACT

Cobalt is the main component of metal prostheses in hip arthroplasty. Studies have shown that metal particles mainly composed of cobalt nanoparticles (CoNPs) can cause systemic and local toxic reactions due to various physical and chemical factors. Therefore, elucidating the underlying mechanisms of metal prosthetic action, coupled with the identification of effective detoxification drugs is imperative to minimizing postoperative complications and prolonging the service life of these clinical tools. In this study, we treated Balb/3T3 mouse fibroblast cell line with CoNPs and ferrostatin-1, then measured cell viability via the CCK-8 assay. Next, we determined levels of reactive oxygen species (ROS), malondialdehyde (MDA), glutathione (GSH), cobalt and iron contents, as well as glutathione peroxidase 4 (GPX4), and solute carrier family 7 member 11 (SLC7A11) expression in each group. Finally, we employed transmission electron microscopy (TEM) to detect changes in the ultrastructure of each group of cells. Exposure of cells to CoNPs significantly suppressed their viability, and downregulated expression of GSH, GPX4, and SLC7A11 proteins. Conversely, this treatment mediated a significant increase in ROS, MDA, cobalt, and iron levels in the cells. TEM images revealed a marked increase in density of the mitochondrial membrane of cells in the CoNPs group, while the outer membrane was broken. Notably, treatment with ferroptosis inhibitor Ferrostatin-1 alleviated the cytotoxic response caused by CoNPs. These findings suggest that CoNP-induced cytotoxicity may be closely related to ferroptosis, indicating that inhibition of ferroptosis is a potential therapeutic strategy for reducing CoNP toxicity.

CONTACT Yake Liu yakeliu85@sina.com; Fan Liu liufan19515@126.com Department of Orthopaedics, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, Jiangsu 226001, China

*Weinan Zhang and Chen Wang Contributed Equally to the Article.

© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Millions of people around the world suffer from hip arthritis, with total hip replacement shown to be an effective clinical therapy for treating patients with end-stage arthritis. Since the mid-1980s, more than 1 million hip replacement prostheses, made of cobalt-chromium (CoCr) alloys, have been implanted worldwide [1]. Long-term implantation of metal endoprophes causes Co\textsuperscript{2+} and Cr\textsuperscript{3+} ions to be released by metal particles in the bearings of hip implants, due to influence by physical and chemical factors, such as pH changes, fatigue, wear, fretting, and mechanical stress, among others. This release is caused by crevice corrosion of mechanically assisted tapered connection modules, including head-neck and neck-shank tapered interfaces [2,3]. Previous studies have proved that wear and corrosion particles extracted from surrounding tissues of devices are mainly in the nanometer size range. Notably, the particles are generally smaller than 50 nm, with a round and irregular morphology [4].

Patients undergoing total hip replacement manifest femoral osteolysis, with 29% of these patients exhibiting elevated levels of Co\textsuperscript{2+} in the blood during long-term follow-up [5]. This is because CoNPs are easily taken up by macrophages in tissues and transported to the phagolysosomes in the cells, which predisposes them to lysis and a large amount of Co\textsuperscript{2+} [6]. Previous studies have shown that Co\textsuperscript{2+} can not only inhibit expression of enzymes and proteins involved in DNA maintenance and repair, but also induce generation of ROS through a Fenton-like reaction in the presence of hydrogen peroxide to cause cell death [7]. Consequently, this causes a series of symptoms of poisoning in the nervous system, cardiovascular system, endocrine system, etc [2\textsuperscript{8–10}]. Therefore, oxidative stress is an important prerequisite for CoNP-induced cytotoxicity.

The term ferroptosis, coined in 2012, describes an iron-dependent, non-apoptotic form of cell death induced by Erastin and RSL3 [10]. Accompanying this discovery was identification of the first small-molecule ferroptosis inhibitor called Ferrostatin-1, an aromatic amine that specifically combines with lipid ROS to protect cells from lipid peroxidation-induced damage [11]. The mechanism underlying ferroptosis action can be roughly divided into two parts, namely the core pathway of ferroptosis and iron metabolism.

Specifically, the core pathway that causes ferroptosis entails accumulation of lipid ROS caused by the inhibition of the cystine/glutamate antiporter system (system Xc\textsuperscript{−}) and GPX4 [12]. Although iron is an essential component for normal functioning of cells, excessive accumulation of free Fe\textsuperscript{2+} can induce ROS production via the Fenton reaction, thereby causing excessive accumulation of fatal lipid peroxides that cause oxidative damage to cells [13,14]. Previous studies have shown that cells exposed to CoNPs exhibit a significantly lower total GSH content during the early stage, and a marked lipid peroxidation effect [15]. More recently, A research has shown that CoNPs can trigger ferroptosis-like cell death in neuronal cells [16]. Notwithstanding the studies conducted to date fall short in terms of providing a detailed understanding of the mechanism of cytotoxicity of CoNPs.

Herein, the present study was aimed to investigate whether Ferrostatin-1 can alleviate cytotoxicity of CoNPs via inhibiting ferroptosis. We hypothesized that ferroptosis plays a key role in CoNP-induced cytotoxicity, while the ferroptosis inhibitor Ferrostatin-1 can effectively suppress this cytotoxicity.

Materials and methods
Characterization and preparation of CoNPs
Characterization of CoNPs (25–30 nm, Alfa Aesar, China) was as described in our previous study. Briefly, the diameter of CoNPs as measured by transmission electron microscope (TEM, JEM-2100 F, Japan), high-resolution scanning electron microscope (Hitachi 550 ultra-high-resolution SEM), and X-ray diffraction (XRD) was about 30 nm [17]. CoNPs were weighed, a day before the experiment, surface sterilized for 4 h at 180°C, and suspended in ultrapure water to prepare a stock solution with a concentration of 40 mM. The solution was sonicated, for 30 min, with an ultrasonic oscillator to disperse the CoNPs, diluted to the target concentration using complete culture medium, then quickly added to the cell sample. Ferrostatin-1 (#HY-100579, MCE) was dissolved in DMSO, at a concentration of 1 mM.
Cell line and cell culture

The mouse fibroblast cell line, Balb/3T3, was purchased from the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM medium supplemented with 10% FBS, and 1% penicillin and streptomycin. All cells were grown in a humidified cell culture incubator, maintained at 5% CO₂ and a temperature of 37°C. The medium was changed every day, and passaged every 2 to 3 days [18].

Analysis of cell viability

Cell viability was determined using the CCK-8 assay kit (#CK04, Dojindo) according to the manufacturer's instructions. Briefly, cells were seeded into a 96-well plate, then 10 μl of the CCK-8 reagent was added to each well and incubated for 2 h in cell culture incubator. Absorbance was then measured at 450 nm, the IC₅₀ (the half maximal inhibitory concentration) value of CoNPs calculated, and the optimal detoxification concentration of Ferrostatin-1 determined [19].

Detection of intracellular cobalt concentration

The Balb/3T3 cells were seeded into a 6-well plate (2 x 10⁵ cells/well) for 24 h, then treated with CoNPs (400 μM) and Ferrostatin-1 (1 μM) for 24 h. Next, the cells washed 3 times with PBS, digested with trypsin via centrifugation and the cell pellet collected. The cells were resuspended in 1 ml PBS, then counted using a cell counter (Thermo Fisher, USA). The cells were centrifuged, supernatant discarded, then lysed on ice for 20 min with 500 μl of lysis buffer. Next, the contents were centrifuged for 20 min (4°C, 12,000 rpm/min), the supernatant collected, and Cobalt concentration in supernatants of samples in each group determined via Inductively coupled plasma mass spectrometry (ICPMS, PerkinElmer NexION 350).

Evaluation of intracellular iron content

Balb/3T3 cells were seeded into a 6-well plate (2 x 10⁵ cells/well) for 24 h, treated with CoNPs (400 μM) and Ferrostatin-1 (1 μM) for 24 h. Next, cells were washed 3 times with PBS, digested with trypsin and the collected. The cells were resuspended in 1 ml PBS, and their number counted using a cell counter. Next, the cells were centrifuged, the supernatant discarded, and the pellet lyzed with 500 μl lysis buffer on a shaker for 2 h. Finally, intracellular Fe²⁺ and total iron concentrations were determined using the Iron Assay Kit (#ab83366, Abcam), according to the manufacturer’s instructions.

Measurement of Reactive Oxygen Species

Balb/3T3 cells were seeded into a 6-well plate (2 x 10⁵ cells/well) for 24 h, treated with CoNPs (400 μM) and Ferrostatin-1 (1 μM) for 24 h, then incubated with the DCFH-DA probe in the ROS kit (#S0033S, Beyotime) for 30 min in the dark. Next, the cells were washed 3 times with PBS, and observed under an inverted fluorescence microscope (Olympus, Japan) at excitation (Ex) and emission (Em) wavelengths of 485 nm and 525 nm, respectively.

Evaluation of malondialdehyde and glutathione

Balb/3T3 cells were seeded and treated mentioned above, collected, and counted on a cell counter. Next, c cellular concentrations of MDA and GSH were measured using MDA and GSH kits (#BC0020; #BC1175, Solarbio) according to the manufacturer’s instructions [20].

Detection of mitochondrial membrane potential

The Balb/3T3 cells were seeded and treated as described above. Cell culture medium was aspirated out, and the cells incubated with Mito-Tracker Red CMXRos and Hoechst 33,342 in the Mito-Tracker Red CMXRos staining solutions, as described by the manufacturer’s instructions of the Mitochondrial Membrane Potential Kit (# C1071S, Beyotime) at room temperature in the dark for 20–30 min. The contents were immediately place in an ice bath, then subjected to inverted fluorescence microscopy for detection of cell fluorescence. Mito-Tracker Red CMXRos and Hoechst 33,342 were detected as red and blue fluorescence, respectively [21].

Western blot analysis

Balb/3T3 cells were first washed twice with PBS, then total proteins extracted from them using the RIPA reagent containing 1% PMSF. Protein concentration
was determined using a Nanodrop one (Thermo Fisher, USA). Equal concentrations of proteins across samples were separated on a 12% SDS-PAGE gel electrophoresis, and transferred to polyvinylidene difluoride (PVDF) membranes (#FFP24, Beyotime). The membranes were blocked, at room temperature, with 5% skimmed milk powder diluted in TBST for 2 h, then incubated overnight with the following primary antibodies at 4°C: anti-GPX4 antibody (1:1000, #ab125066, Abcam), Anti-xCT antibody (1:1000, #ab37185, Abcam), and anti-GAPDH antibody (1:1000, #ab59164, Abcam). The membranes were washed with TBST, then incubated with the Anti-Mouse IgG secondary antibody (1:5000, #L3202, SAB) for 2 h at room temperature. Finally, the blots were stained with a chemiluminescence reagent (#P10300, NCM) and protein expression quantified using the ImageJ software [22].

Transmission electron microscopy

Distribution of CoNPs, inside and outside the cell, as well as changes in cell ultrastructure were detected via TEM. Briefly, cells were treated with CoNPs (400 μM) and Ferrostatin-1 (1 μM) for 24 h, washed twice with PBS, collected via centrifugation and added to the agar solution. After solidification of the agar, cell clumps were fixed with 2.5% glutaraldehyde in 0.1% sodium chloride buffer, rinsed, dehydrated, embedded, and sectioned [23]. Finally, changes in cell ultrastructure were detected under a transmission electron microscope.

Statistical analysis

Data, from at least 3 replicates, were statistically analyzed using GraphPad Prism 9 software and expressed as means with their respective standard deviations (SD). Differences among groups were determined using a one-way analysis of variance (ANOVA), accompanied by a Dunnett’s test. Data followed by P < 0.05 were considered statistically significant.

Results

CoNP cytotoxicity and ferrostatin-1’s detoxification effect in vitro

Results of the CCK-8 assay, after treatment of Balb/3T3 cells with different concentrations of CoNPs, revealed that low CoNPs concentrations had no significant effect on cell viability after 6 h of incubation, and cell viability only decreased significantly after increasing the concentration to more than 800 μM. In contrast, cell viability began to significantly decrease after 48 h of incubating the cells with 200 μM CoNPs. Notably, we observed a steady decrease in cellular activity with increase in CoNP concentration after 24 h (Figure 1a). Therefore, we based on cell viability at 24 h and calculated the IC_{50} value of CoNPs to be about 400 μM, then used CoNP concentration of 400 μM in subsequent experiments. Exposure of Balb/3T3 cells with different concentrations of Ferrostatin-1 for 24 h resulted in no significant change in cell viability, compared with the control group (Figure 1b). Subsequently, we used 400 μM CoNPs and different concentrations of Ferrostatin-1 to treat the cells over a 24-h period, and found that the cell survival rate was highest at 1 μM Ferrostatin-1 (Figure 1c-d). This was chosen as the optimal detoxification concentration of Ferrostatin-1.

Ferrostatin-1 reduces levels of ROS and MDA in CoNP-treated Balb/3T3 cells

Ferroptosis mainly manifests as lipid peroxidation caused by accumulation of ROS. Therefore, we quantified levels of intracellular ROS and concentration of lipid peroxidation product MDA. Results showed that Balb/3T3 cells treated with CoNPs (400 μM) for 24 h significantly elevated ROS and MDA levels relative to the control group, while addition of Ferrostatin-1 effectively reversed this phenomenon (Figure 2a-e).

Ferrostatin-1 upregulates GSH, GPX4, and SLC7A11 expression in CoNP-treated Balb/3T3 cells

Previous studies have shown that system Xc − enters cystine, which is reduced to cysteine during GSH synthesis, while GPX4 uses GSH to eliminate lipid peroxides formed by phospholipids containing polyunsaturated fatty acids [24]. In the present study, we detected intracellular GSH via spectrophotometry, and found that the intracellular GSH was significantly reduced in the CoNPs group....
alone, compared to the control group, while addition of Ferrostatin-1 could effectively inhibit GSH depletion (Figure 3a). In addition, Western blots showed that CoNP treatment significantly downregulated expression of GPX4 and SLC7A11 proteins, after 24 h relative to the control group. Conversely, addition of Ferrostatin-1 reversed this phenomenon (Figure 3b-d).
Effect of Ferrostatin-1 on cobalt and iron content in CoNP-treated Balb/3T3 cells

CoNPs’ affinity to bind to the plasma membrane, coupled by its uptake by cells, are necessary prerequisites for development of CoNP toxicity [25]. Here, we measured levels of cobalt in cells using ICP-MS and found that this content significantly increased after 24 h of CoNPs treatment relative to the control group. However, addition of Ferrostatin-1 reduces cellular cobalt uptake ability in cells (Figure 4a). Iron overload has been implicated in lipid peroxidation and development of ferroptosis. We employed an Iron Assay Kit to determine iron content in cells and found that those in the CoNPs treatment group recorded significantly higher intracellular Fe$^{2+}$ and total iron concentrations than the control group. However, cells exposed to both CoNPs and Ferrostatin-1 recorded significantly lower concentrations of Fe$^{2+}$ and total iron than those treated with CoNPs alone (Figure 4b).

Ferrostatin-1 suppresses CoNP-induced mitochondrial damage in Balb/3T3 cells

Previous studies have shown that ferroptosis can cause damage to the cell’s mitochondria, thereby causing a decrease in mitochondrial membrane potential [26]. Results of the present study showed that treatment of cells with CoNPs significantly lowered their mitochondrial membrane potential compared to those in the control group. However, addition of Ferrostatin-1 significantly inhibited the decrease in mitochondrial membrane potential caused by CoNPs (Figure 5a-d). Ferroptosis in cells under electron microscopy is mainly manifested as mitochondrial damage, while there are almost no other obvious changes in cellular morphology prior to its death [10,27]. Results of the present study revealed that cells in the control and the Ferrostatin-1 groups had normal mitochondrial structure. Compared to the control group, treatment with CoNPs alone caused the mitochondrial outer membrane of the cells to break, and this was accompanied by an increase in membrane density, as well as disappearance of mitochondrial cristae. Results from the cotreatment group of CoNPs and Ferrostatin-1 showed that although cells still had some visible increase in mitochondrial membrane density, there was no membrane fragmentation (Figure 5e-h). This indicates that Ferrostatin-1 can protect cells from CoNP-induced cytotoxic damage to the ultrastructure.

Figure 3. Ferrostatin-1 improves CoNPs-induced expression of GSH, GPX4, and SLC7A11 proteins in Balb/3T3 cells. (a) Levels of intracellular GSH across different treatment groups. (b-d) Western blots showing expression of GPX4 and SLC7A11 proteins. All the data are shown as mean ± SD of at least 3 replicates. **p < 0.01 versus the control group. ## p < 0.01 versus the CoNPs group.
Discussion

Hip replacement is usually accompanied by deposition of metal wear particles in the surrounding tissues of the prosthesis caused a series of adverse reactions [28]. Although clinical therapies for treatment of acute cobalt poisoning have mainly focused on plasma exchange, or use of multiple chelating agents to reduce cobalt concentration in blood, the therapeutic effect remains unclear. Adverse reactions caused by chronic cobalt poisoning are mainly controlled through repair and removal of prostheses. However, surgery is not an efficacious treatment option for elderly patients or those that cannot withstand revision surgery [29,30]. Therefore, elucidating the underlying mechanism of CoNP-induced cytotoxicity and identification of efficacious detoxification methods are imperative to effective management of the condition. Results from our previous studies have confirmed that CoNPs can induce peroxidation through excessive production of ROS, which leads to apoptosis of Balb/3T3 cells, while the associated cytotoxicity can be inhibited using antioxidants [31]. However, in-depth research revealed that apoptosis is not the main mechanism of CoNP-induced cell death in Balb/3T3. We detected ferroptosis indicators in Balb/3T3 cells treated with Alpha lipoic acid and CoNPs, and found that CoNPs disrupted iron

![Figure 4](image1.png)

**Figure 4.** Ferrostatin-1 treatment significantly affects Cobalt and Iron concentration in Balb/3T3 cells. (a) ICP-MS spectrum showing the concentration of Cobalt in cells across different treatment groups. (b) Iron concentrations in cells across different treatment groups after iron assay. All the data are shown as mean ± SD of at least 3 replicates. **p < 0.01 versus the control group. ***p < 0.01 versus the CoNPs group.

![Figure 5](image2.png)

**Figure 5.** Ferrostatin-1 protects Balb/3T3 cells from CoNPs-induced toxic damage. (a-d) Cell observation under an inverted fluorescence microscope (magnification = 400X). Red fluorescence denotes mitochondrial membrane potential detected by the MitoTracker Red probe. (e-h) Ultrastructure of cells as observed under a TEM. The yellow arrows indicate CoNPs in the cytoplasm, while the red arrows indicate the mitochondria.
stability and caused the accumulation of lipid peroxides [32]. Therefore, apart from apoptosis, CoNP-induced cytotoxicity can also cause ferroptosis.

Ferroptosis, a form of cell death characterized by accumulation of lipid ROS and iron in cells, has been detected in multiple system diseases, such as cancer, subarachnoid hemorrhage, lung and kidney injury, and osteoarthritis [33–38]. Ferrostatin-1, a highly effective free radical trapping antioxidant (RTA) compound, has been shown to effectively inhibit ferroptosis and is associated with excellent protective efficacy across both in vivo and in vitro disease models [39–41]. To date, nothing is known regarding the mechanism through which CoNPs cause ferroptosis. To our knowledge, this is the first report describing Ferrostatin-1 as an antidote to CoNP-induced toxicity.

Summarily, our experimental results showed that low CoNPs concentrations can stimulate growth of Balb/3T3 cells, but an increase in concentration induces marked toxic effect on cells. Conversely, addition of Ferrostatin-1 significantly alleviates these toxic effects. ROS accumulation causes an increase in lipid peroxidation products, which is an important feature of ferroptosis. Results from the present study showed that Ferrostatin-1 can significantly reduce CoNP-induced ROS levels in Balb/3T3 cells as well as MDA production. Previous studies have shown that system Xc− is an important part of the cell synthesis of GSH, while GPX4 uses GSH as a cofactor to inhibit lipoxygenase-mediated lipid peroxidation [42,43]. Results of the present study showed that Ferrostatin-1 effectively increased the level of GSH in Balb/3T3 cells caused by CoNPs. In addition, Western blots showed that treatment of Balb/3T3 cells with CoNPs resulted in downregulation of GPX4 and SLC7A11 proteins, although Ferrostatin-1 could inhibit this decrease.

Cellular uptake of CoNPs is a prerequisite for development of toxicity. In the present study, TEM images revealed a marked deposition of CoNPs in the cytoplasm, but none in the nucleus. Moreover, it was evident that Ferrostatin-1 can prevent cobalt uptake by Balb/3T3 cells. Interestingly, Ferrostatin-1 could effectively suppress CoNPs-induced increase in iron (including Fe2+ and total iron concentration) levels in Balb/3T3 cells. This was consistent with findings from a previous study that concluded that ferritin degradation causes unstable iron overload and leads to ferroptosis [44]. Finally, we found that CoNPs treatment mediated a decrease in cell mitochondrial membrane potential and destruction of mitochondrial membrane structure in Balb/3T3 cells. Conversely, exposure to Ferrostatin-1 effectively reversed these phenomena, increasing mitochondrial membrane potential and maintaining the mitochondrial shape.

**Conclusion**

Hip arthroplasty is usually accompanied by wearing out of the metal prosthesis and release of CoNPs. This release causes a series of local or systemic adverse reactions, which seriously affect the patient’s physical and mental health. Previous studies, exploring the detoxification mechanism of CoNPs, have only used some common antioxidants based on the oxidative stress mechanism. In the present study, we demonstrated that CoNPs can cause ferroptosis in Balb/3T3 cells, while ferroptosis inhibitor, Ferrostatin-1, can effectively protect the cells from this toxicity. Taken together, our findings lay a foundation for further exploration into the signaling pathways that regulate CoNP-induced ferroptosis in Balb/3T3 cells, and are also expected to guide in vivo experiments.

**Acknowledgements**

Not applicable.

**Disclosure statement**

No potential conflict of interest was reported by the author(s).

**Funding**

This work was supported by the [Postgraduate Research & Practice Innovation Program of Jiangsu Province] under Grant [number SJCX20_1167]; [Youth Science Foundation Project of National Natural Science Foundation of China] under Grant [number 82002282]; and [National Natural Science Foundation of China (General Program)] under Grant [number 82172519].
References

[1] GS Matharu, SJ Mellon, DW Murray, HG Pandit, et al. Follow-up of metal-on-metal hip arthroplasty patients is currently not evidence based or cost effective. J Arthroplasty. 2015;30(8):1317–1323. doi:10.1016/j.arth.2015.03.009.

[2] Leyssens Laura, Vinck Bart, Der Straeten Catherine Van, Wuys Floris, Maes Leen, et al. Cobalt toxicity in humans-A review of the potential sources and systemic health effects. Toxicology. 2017;387:43–56. doi:10.1016/j.tox.2017.05.015.

[3] Borgese M, Rossi F, and Bonfanti P, et al. Recovery ability of human adipose stem cells exposed to cobalt nanoparticles: outcome of dissolution. Nanomedicine (Lond). 2020;15(5):453–465. doi:10.2217/nmm-2019-0195.

[4] Xu J, Yang J, and Nyga A, et al. Cobalt (II) ions and nanoparticles induce macropage retention by ROS-mediated down-regulation of RhoA expression. Acta Biomater. 2018;72:434–446. doi:10.1016/j.actbio.2018.03.054.

[5] Reiner T, Klotz MC, Seelmann K, et al. Long-Term Results of a Second-Generation, Small-Diameter, Metal-On-Metal Bearing in Primary Total Hip Arthroplasty at 14-year Follow-Up. Materials (Basel). 2020;13(3). DOI:10.3390/ma13030557

[6] Madl A, Ljong M, and Kovochich M, et al. Toxicology of wear particles of cobalt-chromium alloy metal-on-metal hip implants Part I: physicochemical properties in patient and simulator studies. Nanomedicine Nanotechnology, Biology and Medicine. 2015;11(5):1201–1215. doi:10.1016/j.nano.2014.12.005.

[7] Lison D, van den Brule S, and Van Maele-Fabry G. Cobalt and its compounds: update on genotoxic and carcinogenic activities. Crit Rev Toxicol. 2018;48(7):522–539. doi:10.1080/10408444.2018.1491023.

[8] Green B, Griffiths E, and Almond S. Neuropsychiatric symptoms following metal-on-metal implant failure with cobalt and chromium toxicity. BMC Psychiatry. 2017;17(1):33. doi:10.1186/s12888-016-1174-1.

[9] Oyagbemi O, Omobowale TO, and Awoyomi OV, et al. Cobalt chloride toxicity elicited hypertension and cardiac complication via induction of oxidative stress and upregulation of COX-2/Bax signaling pathway. Hum Exp Toxicol. 2019;38(5):519–532. doi:10.1177/0960327118812158.

[10] Dixon S, Lemberg K, and Lamprecht M, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–1072. doi:10.1016/j.cell.2012.03.042.

[11] Cao J, Dixon S. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016;73(11–12):2195–2209.

[12] Fang Yuanjian, Gao Shiqi, Wang Xiaooyu, Cao Yang, Zhang Jianmin, et al. Programmed cell deaths and potential crosstalk with blood-brain barrier dysfunction after hemorrhagic stroke. Front Cell Neurosci. 2020;14:68. doi:10.3389/fncel.2020.00068.

[13] Bresgen Nikolaus, Jaksch Heidi, Lacher Heide, M Eckl Peter, et al. Iron-mediated oxidative stress plays an essential role in ferritin-induced cell death. Free Radic Biol Med. 2010;48(10):1347–1357. doi:10.1016/j.freeradbiomed.2010.02.019.

[14] G B. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012;2012:137289. doi:10.5402/2012/137289.

[15] Sabbioni Enrico, Fortaner Salvador, Farina Massimo, Petrarca Claudia, Di Gioacchino Mario, et al. Cytotoxicity and morphological transforming potential of cobalt nanoparticles, microparticles and ions in Balb/c3T3 mouse fibroblasts: an in vitro model. Nanotoxicology. 2014;8(4):455–464 doi:10.3109/17435390.2013.796538.

[16] Gupta Govind, Gliga Anda, Hedberg Jonas, Serra Angela, Fadeel Bengt, et al. Cobalt nanoparticles trigger ferroptosis-like cell death (oxygenis) in neuronal cells: potential implications for neurodegenerative disease. FASEB J. 2020;34(4):5262–5281 doi:10.1096/fj.201902191RR.

[17] Liu Yake, Hong Hongxiang, Lu Xu, Liu Fan, Yang Huilin, et al. L-ascorbic acid protected against extrinsic and intrinsic apoptosis induced by cobalt nanoparticles through ROS attenuation. Biol Trace Elem Res. 2017;175(2):428–439 doi:10.1007/s12011-016-0789-x.

[18] Zhu Zhaoliang, Duan Peng, Song Huping, Zhou RongLe, Chen Tao, et al. Downregulation of Circular RNA PSEN1 ameliorates ferroptosis of the high glucose treated retinal pigment epithelial cells via miR-200b-3p/cofilin-2 axis. Bioengineering. 2021;12(2):12555–12567 doi:10.1080/21655979.2021.2010369.

[19] Zhang Wenjing, Sun Yu, Bai Lu, Zhi Lili, Wang Yang, et al. RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J Clin Invest. 2021;131(22):e152067 doi:10.1172/JCI152067.

[20] Guo Jingyi, Duan Lifan, He Xueying, Li Shengbiao, Liu Xingguo, et al. A combined model of human iPSC-derived liver organoids and hepatocytes reveals ferroptosis in DGUOK mutant mtDNA depletion syndrome. Adv Sci (Weinheim, Baden-Wurttemberg, Germany). 2021;8(10):2004680 doi:10.1002/advs.202004680.

[21] Cartes-Saavedra Benjamin, Macuada Josefa, Lagos Daniel, Arancibia Duxan, Eisner Verónica, et al. OPA1 modulates mitochondrial Ca uptake through ER-mitochondria coupling. Front Cell Dev Biol. 2021;9:774108 doi:10.3389/fcell.2021.774108.

[22] Wu Anqi, Li Yi, Kong Mingzhu, Zhu Baihui, Wang Feng, et al. Upregulated hsa_circ_005705 facilitates
cell growth and metastasis of hepatocellular carcinoma through the miR-578/april axis. Front Oncol. 2020;10:1388 doi: 10.3389/fonc.2020.01388.

23. Chu Jun, Liu chenxu, Song Rui, Li Qinglin, et al. Ferrostatin-1 protects HT-22 cells from oxidative toxicity. Neural Regen Res. 2020;15(3):528–536 doi:10.4103/1673-5374.266060.

24. Stockwell Brent R, Bayir Hülya, Fulda Simone, Zhang Donna D, et al. Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–285 doi:10.1016/j.cell.2017.09.021.

25. Papis Elena, Rossi Federica, Raspanti Mario, Colombo Graziano, Gornati Rosalba, et al. Engineered cobalt oxide nanoparticles readily enter cells. Toxicol Lett. 2009;189(3):253–259 doi:10.1016/j.toxlet.2009.06.851.

26. Hinder L, Pfaff A L, Emmerich R E, Michels S, Schlitzer M, Culmsee C, et al. Characterization of novel diphenylamine compounds as ferroptosis inhibitors. J Pharmacol Exp Ther. 2021 Aug;378(2):184-196 doi:10.1124/jpet.121.100534.

27. Abrams R, Carroll W, and Woerpel K. Five-membered ring peroxide selectively initiates ferroptosis in cancer cells. ACS Chem Biol. 2016;11(5):1305–1312 doi:10.1021/acschembio.5b00900.

28. Mahendra Gayana, Pandit Hemant, Kliskey Karolina, Murray David, Athanasou Nick, et al. Necrotic and inflammatory changes in metal-on-metal resurfacing hip arthroplasties. Acta Orthop. 2009;80(6):653–659 doi:10.3109/17453670903470316.

29. Grant Michelle L, Karp, Julie K, Palladino Michele, Le Nguyen, Herman Jay H, et al. Does therapeutic plasma exchange have a role in the treatment of prosthetic hip-associated cobalt toxicity? A case report and literature review. Transfusion. 2016;56(9):2368–2373 doi:10.1111/trf.13720.

30. Zywiol M G, Cherian J J, Banerjee S, Cheung A C, Mont M A, et al. Systemic cobalt toxicity from total hip arthroplasties: review of a rare condition Part 2. measurement, risk factors, and step-wise approach to treatment. Bone Joint J. 2016 Jan;98-B(1):14–20 doi:10.1302/0303-6020.98B1.36712.

31. Yan Xin, Liu Yake, Xie Tian, Liu Fan, et al. α-Tocopherol protected against cobalt nanoparticles and coal induced cytotoxicity and inflammation in Balb/ 3T3 cells. Immunopharmacol Immunotoxicol. 2018;40(2):179–185 doi:10.1080/08923973.2018.1424901.

32. Liu Yake, Zhu Wenfeng, Zhang Weinan, Liu Fan, et al. Alpha lipoic acid antagonizes cytotoxicity of cobalt nanoparticles by inhibiting ferroptosis-like cell death. J Nanobiotechnology. 2020;18(1):141 doi:10.1186/s12951-020-00700-8.

33. Kuang Feimei, Liu Jiao, Xie Yangchun, Tang Daolin, Kang Rui, et al. MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells. Cell Chem Biol. 2021;28(6):765–775.e5 doi:10.1016/j.chembiol.2021.01.006.

34. Liu Xiechuang, Zhu Xinyang, Qi Xin, Meng Xianwei, Xu Ke, et al. Co-administration of rGD with sorafenib-loaded iron-based metal-organic framework as a targeted ferroptosis agent for liver cancer therapy. Int J Nanomedicine. 2021;16:1037–1050 doi:10.2147/ijn.s292528.

35. Zheng Bao, Zhou Xiwei, Pang Lujun, Che Yanjun, Qi Xin, et al. Baicalin suppresses autophagy-dependent ferroptosis in early brain injury after subarachnoid hemorrhage. Bioengineer. 2021;12(1):7794–7804 doi:10.1080/21655979.

36. Liu Pengfei, Feng Yetong, Li Hanwei, Chen Xin, Zhao Lei, et al. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis. Cell Mol Biol Lett. 2020;25:10 doi:10.1186/s11658-020-00205-0.

37. Meng Xiaoyan, Huang Wenjing, Mo Weiwei, Shu Tingting, Ning Haibo, et al. ADAMTS-13-regulated nuclear factor E2-related factor 2 signaling inhibits ferroptosis to ameliorate cisplatin-induced acute kidney injury. Bioengineer. 2021 Dec;12(2):11610-11621 doi:10.1080/21655979.2021.1994707.

38. Zhou Xueman, Zheng Yingchong, Sun Wentian, Zhang Zhenzen, Liu Jin, et al. D-mannose alleviates osteoarthritis progression by inhibiting chondrocyte ferroptosis in a HIF-2α-dependent manner. Cell Prolif. 2021 Nov;54(11):e13134. doi:10.1111/cpr.13134.

39. Hu Bing, Liu Yunsheng, Chen Xiaochu, Zhao Jianjun, Nie Guohui, et al. Ferrostatin-1 protects auditory hair cells from cisplatin-induced ototoxicity in vitro and in vivo. Biochem Biophys Res Commun. 2020;533(4):1442–1448 doi:10.1016/j.bbrc.2020.10.019.

40. Zilka Omkar, Shah Ron, Li Bo, Conrad Marcus, A Pratt Derek, et al. On the mechanism of cytoprotection by ferrostatin-1 and liproxstatin-1 and the role of lipid peroxidation in ferroptotic cell death. ACS Cent Sci. 2017;3(3):232–243 doi:10.1021/acscentsci.7b00028.

41. Fang Xuexian, Wang Hao, Han Dan, Min Junxia, Wang Fudi, et al. Ferroptosis as a target for protection against cardiomyopathy. Proc Natl Acad Sci U S A. 2019;116(7):2672–2680 doi:10.1073/pnas.1821022116.

42. Massie Ann, Boillée Séverine, Hewett Sandra, Knackstedt Lori, Lewerenz Jan, et al. Main path and byways: non-vesicular glutamate release by system xc (-) as an important modifier of glutamatergic neurotransmission. J Neurochem. 2015;135(6):1062–1079 doi:10.1111/jncc.13348.

43. Conrad M, and Friedmann Angeli J. Glutathione peroxidase 4 (Gpx4) and ferroptosis: what’s so special about it? Mol Cell Oncol. 2015;2(3);e995047 doi:10.4161/23723556.2014.995047.

44. Ajoolabady Amir, Aslkhodapassandhokamab Hadim, Libby Peter, Tuomilehto Jaakko, Ren Jun, et al. Ferritinophagy and ferroptosis in the management of metabolic diseases. Trends Endocrinol Metab. 2021;32(7):444–462 doi:10.1016/j.tem.2021.04.010.